Surfactant administration is the delivery of a liquid medication directly into a newborn’s lungs to replace pulmonary surfactant, a slippery coating that premature babies often lack. Without it, the tiny air sacs in the lungs collapse with each breath, making gas exchange impossible. Since its introduction in the late 1980s, giving surfactant to premature infants with respiratory distress syndrome has become one of the most impactful interventions in neonatal medicine, cutting the risk of death and serious lung complications substantially. The procedure sounds straightforward, but the details of who gets it, when, how, and which formulation matter more than most people realize.
What Pulmonary Surfactant Does in the Lungs
Your lungs contain hundreds of millions of tiny air sacs called alveoli. These sacs are lined with a thin layer of liquid, and that liquid creates surface tension, the same force that makes water bead on a countertop. Left unchecked, surface tension would cause the alveoli to collapse inward, especially during exhalation when they get smaller. Pulmonary surfactant is a mixture of fats and proteins that coats this liquid layer and dramatically lowers surface tension. When the alveoli shrink during a breath out, the surfactant film compresses and drives surface tension down to near zero, keeping the sacs from sticking shut.1PubMed Central. The biophysical function of pulmonary surfactant
The mixture is roughly 90 percent lipids and 10 percent proteins by weight. Among the proteins, two small hydrophobic ones called SP-B and SP-C are critical. SP-B is arguably the single most important component: without it, the surfactant film cannot form at all, and oxygen cannot reach the blood.2PubMed Central. Surfactant Proteins SP-B and SP-C in Pulmonary Surfactant Monolayers: Physical Properties Controlled by Specific Protein–Lipid Interactions SP-B and SP-C act like molecular keys that trigger the unpacking and spreading of surfactant across the air-liquid interface.3Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. A small key unlocks a heavy door: The essential function of the small hydrophobic proteins SP-B and SP-C to trigger adsorption of pulmonary surfactant lamellar bodies Two other proteins, SP-A and SP-D, play a different role: they help the immune system by recognizing and tagging invaders in the lungs.4PubMed Central. The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections
Why Premature Babies Need It
Babies born very early, especially before 28 weeks of gestation, have lungs that simply have not had time to produce enough surfactant on their own. After birth, they struggle to keep their alveoli open, and the result is respiratory distress syndrome, or RDS. The lungs stiffen, oxygen levels drop, and the infant needs breathing support almost immediately.5Breathe. Pulmonary surfactant in newborn infants and children Before exogenous surfactant became available, RDS was the leading cause of death in premature newborns. The story of how the treatment reached bedside care is a long one involving decades of research, but the key turning point came in the 1980s when clinical trials showed that instilling surfactant into the lungs of these infants dramatically improved survival.
Surfactant deficiency is not the only reason a newborn’s lungs can fail. Meconium aspiration syndrome, where a baby inhales its own stool during delivery, causes a different kind of surfactant problem. Meconium fragments surfactant lipids and proteins and triggers inflammation that inactivates both the baby’s natural surfactant and any therapeutic surfactant given afterward.6Pediatric Research. Meconium-induced inflammation and surfactant inactivation: specifics of molecular mechanisms In these cases, repeated or higher doses of surfactant may be needed, and the response tends to be less predictable than in straightforward RDS.
Types of Surfactant Preparations
Surfactant medications come in two broad categories: those extracted from animal lungs and those made synthetically. Animal-derived surfactants, harvested from calf or pig lungs, contain the natural surfactant proteins SP-B and SP-C. Older synthetic surfactants were protein-free, relying entirely on lipids. That protein gap turned out to matter a great deal.
A large Cochrane review found that animal-derived surfactants outperformed protein-free synthetics in several important ways. Infants treated with animal surfactant had a lower risk of pneumothorax (collapsed lung) by about a third and a small but real reduction in mortality.7PubMed Central. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome Animal-derived preparations also produced faster improvements in oxygenation and lung compliance after dosing. The tradeoff was a slightly elevated risk of necrotizing enterocolitis, a serious gut complication, though no increase in severe brain bleeding.8PubMed. Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents?
Newer-generation synthetic surfactants have closed the gap considerably. By incorporating peptides that mimic the action of SP-B, products like lucinactant performed at least as well as animal-derived options in head-to-head trials and better than the older protein-free synthetics.9PubMed. Animal-derived surfactants versus past and current synthetic surfactants: current status The direction of the field is toward synthetic preparations that can replicate protein function without the variability and supply-chain issues inherent in animal-sourced products, though animal-derived surfactants remain the most widely used worldwide.
How Surfactant Is Given
The original method of administration involves inserting a breathing tube into the infant’s windpipe and instilling the surfactant as a liquid bolus directly into the lungs. The baby is then placed on a mechanical ventilator for ongoing breathing support. This approach works, but mechanical ventilation itself carries risks including lung injury, infection, and chronic lung disease. The push over the past two decades has been to deliver surfactant while avoiding or minimizing time on the ventilator.
The INSURE Technique
INSURE stands for intubation, surfactant administration, and rapid extubation. The baby gets a breathing tube just long enough to receive the surfactant and is then quickly taken off the ventilator and switched to gentler support like nasal continuous positive airway pressure, or CPAP. The idea is to get the surfactant into the lungs without leaving the baby on a machine that can damage them. INSURE is widely used and generally effective, though it does not always succeed. Some infants, particularly those who are very small or have more severe disease, fail the extubation step and end up back on the ventilator anyway.10PubMed. Early Predictors for INtubation-SURfactant-Extubation Failure in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Systematic Review One randomized trial found that using a laryngeal mask airway instead of a standard breathing tube actually reduced the proportion of babies needing mechanical ventilation afterward, partly because it avoided the sedation drugs required for intubation.11Journal of Perinatology. Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery
Less Invasive Surfactant Administration
The latest advance is called LISA, for less invasive surfactant administration, sometimes also called minimally invasive surfactant therapy (MIST). Instead of a full breathing tube, a thin flexible catheter is threaded into the baby’s windpipe while the infant breathes on CPAP. The surfactant drips in over a minute or two, and the catheter is removed. No intubation, no ventilator. Multiple randomized trials and meta-analyses have shown that LISA reduces the need for mechanical ventilation, lowers the incidence of chronic lung disease, and decreases the risk of serious brain bleeding compared to conventional approaches.12PubMed Central. Less invasive surfactant administration: best practices and unanswered questions A systematic review of thin-catheter delivery found roughly a 40 percent reduction in chronic lung disease and a 40 percent reduction in the need for mechanical ventilation within the first 72 hours. The tradeoff is a higher rate of surfactant reflux, where some of the liquid bubbles back up, though this did not translate into worse outcomes overall.13PubMed. Efficacy and safety of surfactant administration via thin catheter in preterm infants with neonatal respiratory distress syndrome: A systematic review and meta-analysis
Nebulized Surfactant
The most ambitious goal is to skip all tubes entirely and deliver surfactant as an aerosol through a face mask or nasal prongs. Early results are encouraging in the sense that nebulized surfactant is safe and well tolerated, but the clinical benefit has been inconsistent. The problem is getting enough of the drug deep into the lungs: much of the aerosol gets lost in the upper airways or exhaled before reaching the alveoli.14PubMed Central. Non-Invasive Surfactant Administration in Preterm Infants Vibrating mesh nebulizers appear to deliver surfactant more efficiently than older jet or ultrasonic devices, and a small pilot study showed rates of repeat dosing comparable to conventional methods in babies of at least 28 weeks’ gestation.15PubMed. Nebulized surfactant in preterm neonates ≤34 weeks of gestation with respiratory distress syndrome: a pilot study No nebulized surfactant product has received regulatory approval yet, and large confirmatory trials are still underway.
What Happens in the Lungs After a Dose
The response to surfactant can be dramatic. Within minutes of administration, the volume of air the baby’s lungs can hold increases substantially. One early study documented increases in lung volume ranging from about 56 percent to over 300 percent immediately after dosing, with a corresponding improvement in blood oxygen levels.16PubMed. Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distention That initial jump in oxygenation comes from previously collapsed alveoli reopening and participating in gas exchange again.
The mechanics are a bit more nuanced than they first appear. Airway resistance actually rises temporarily after dosing because the liquid surfactant briefly occupies space in the airways before spreading to the alveolar surfaces. Over about 90 minutes, lung compliance improves and blood oxygen levels roughly double. Whether the surfactant is given as a rapid bolus or a slow infusion does not change the final outcome much, though oxygenation tends to improve faster after a bolus.17PubMed. Sequential changes in compliance and resistance after bolus administration or slow infusion of surfactant in preterm infants
When to Give It and How Early Matters
Timing is one of the most debated aspects of surfactant therapy. For decades, the question was whether to give surfactant to all very premature babies right away (prophylaxis) or wait to see who develops problems (rescue). The evidence now favors a nuanced middle ground. With the widespread use of antenatal steroids given to mothers before delivery and early CPAP support, universal prophylactic surfactant no longer provides a net benefit.18Paediatrics & Child Health. Guidelines for surfactant replacement therapy in neonates But once an infant does show signs of RDS, giving surfactant early rather than waiting makes a significant difference.
A Cochrane review comparing early versus delayed selective treatment found that early surfactant reduced newborn mortality by about 16 percent, cut the risk of pneumothorax by roughly 30 percent, and decreased the risk of air leak syndromes by nearly 40 percent.19PubMed Central. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome The practical question for clinicians is how much oxygen the baby needs before triggering surfactant delivery. A network meta-analysis found that giving surfactant when supplemental oxygen requirements reach around 40 to 45 percent was a reasonable threshold for babies born at or before 30 weeks, as waiting until higher oxygen requirements appeared to increase the risk of major complications.20PubMed Central. Clinical decision thresholds for surfactant administration in preterm infants: a systematic review and network meta-analysis
Risks and Side Effects
Surfactant administration is generally safe, but it is not risk-free. One of the most serious complications is pulmonary hemorrhage, bleeding into the lungs. This occurs in roughly 3 to 5 percent of ventilated premature infants with severe RDS who receive surfactant, and the risk is higher in babies who also have a patent ductus arteriosus (an abnormal blood vessel connection near the heart).21PubMed Central. Surfactant for pulmonary haemorrhage in neonates One study found that the rate of pulmonary hemorrhage was several times higher in surfactant-treated infants compared to untreated ones.22Pediatric Research. 117 Early and Late Adverse Effects Following Surfactant Therapy The mechanism seems to involve the sudden improvement in lung compliance after surfactant, which can shift blood flow patterns and stress fragile pulmonary vessels.
The act of instilling the surfactant itself can cause transient problems. In a prospective study of 39 infants, about half experienced some complication during the procedure. Most were minor, like temporary drops in oxygen saturation or heart rate, but six infants developed severe airway obstruction during the instillation. Five of those were extremely low birth weight babies with more severe lung disease.23PubMed Central. Severe airway obstruction during surfactant administration using a standardized protocol: a prospective, observational study These risks are manageable in a well-equipped neonatal unit with experienced staff, but they underscore why surfactant therapy belongs in a supervised intensive care setting.
Why Surfactant Has Not Worked Well in Adults
Given how transformative surfactant has been for premature babies, it was natural to wonder whether it could help adults with acute respiratory distress syndrome, or ARDS, a condition where the lungs become severely inflamed and fluid-filled. Multiple trials tested this idea, and the results were disappointing. Two separate meta-analyses found that exogenous surfactant did not reduce mortality in adults with ARDS compared to standard care. One pooled analysis of seven trials found essentially no difference in 28 to 30 day death rates, regardless of whether the surfactant was synthetic, animal-derived, or protein-containing.24PubMed Central. Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis A second meta-analysis similarly showed no mortality benefit, though there was a trend toward improved oxygenation that did not reach statistical significance.25PubMed Central. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis
The failure likely comes down to biology. In premature infants, the core problem is a simple deficiency: the lungs have not made enough surfactant yet, and replacing it addresses the root cause. In adult ARDS, the lungs are inflamed and leaking protein-rich fluid into the air spaces. That fluid actively degrades and inactivates the surfactant you give. The adult lung is also vastly larger, meaning you need much more surfactant to coat the entire surface, and delivering a uniform dose is far harder. The problem in adult ARDS is not just missing surfactant; it is a hostile environment that destroys surfactant faster than you can provide it.
Access in Low-Resource Settings
Prematurity is a leading cause of newborn death globally, and the burden falls disproportionately on low- and middle-income countries where surfactant therapy often is not available. The barriers are interconnected: surfactant is expensive, mechanical ventilators needed for conventional delivery methods are scarce, health insurance coverage is limited, and families frequently must pay out of pocket. With fewer ventilators, clinicians get less practice with neonatal intubation, which makes the procedure riskier and further discourages surfactant use.26The Lancet. Implementing less invasive surfactant administration in Nigeria: a prospective cohort study with a retrospective matched control LISA is seen as a potential solution here because it does not require a ventilator, just CPAP equipment and a thin catheter, which could make surfactant therapy feasible in settings that currently cannot offer it.
Long-Term Outcomes and Two-Year Follow-Up
Parents understandably want to know whether surfactant treatment affects their child’s development down the road. The OPTIMIST-A trial, one of the largest randomized studies of minimally invasive surfactant therapy, followed infants to age two. About 36 percent of infants in both the surfactant group and the control group either died or had neurodevelopmental disability by that point, with no meaningful difference between groups.27JAMA. Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial This is reassuring in an important way: the method of surfactant delivery did not create additional developmental risk. The high overall rate of disability reflects the extreme prematurity of the infants enrolled rather than any harm from the treatment itself.
Surfactant as a Drug Delivery Vehicle
One of the more intriguing research frontiers involves using surfactant not just to stabilize the lungs but as a carrier for other medications. Surfactant naturally spreads across the air-liquid interface of the alveoli with each breath, which makes it a potential vehicle for delivering drugs exactly where they need to go. Laboratory and animal studies have shown that surfactant can efficiently transport hydrophobic drugs like tacrolimus, an anti-inflammatory agent, across lung surfaces. The breathing-like compression and expansion of the surfactant film actually enhances drug release.28PubMed Central. Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations
Closer to clinical use, surfactant has been tested as a vehicle for budesonide, a steroid used to reduce lung inflammation. Delivering budesonide mixed with surfactant directly into the lungs of premature babies decreased the incidence of chronic lung disease or death, a finding that has generated considerable excitement.29PubMed Central. Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration Researchers have also explored surfactant as a carrier for antimicrobial peptides, taking advantage of its spreading properties to distribute infection-fighting agents across the lung surface.30Scientific Reports. Optimizing Exogenous Surfactant as a Pulmonary Delivery Vehicle for Chicken Cathelicidin-2 The vision is a single treatment that stabilizes the lungs and simultaneously delivers anti-inflammatory or anti-infective therapy, turning surfactant from a standalone rescue drug into a platform for targeted lung treatment.
Surfactant Across the Animal Kingdom
Pulmonary surfactant is not unique to humans. All air-breathing vertebrates produce some form of it, but its composition and effectiveness vary widely. Fish, amphibians, and most reptiles produce surfactant with relatively low surface activity, which correlates with their lower body temperatures and simpler lung structures. Warm-blooded animals, including mammals and birds, produce surfactant with much higher surface activity, reflecting their need to ventilate complex, high-surface-area lungs at high metabolic rates.31PubMed. Evolution of surface activity related functions of vertebrate pulmonary surfactant Interestingly, reptiles with higher preferred body temperatures, such as some lizards that bask extensively, also have more active surfactant than their cooler-dwelling relatives. The evolutionary pattern suggests that as lungs became more complex and metabolic demands grew, surfactant had to keep pace. The same biology that makes human lungs so efficient also makes premature human infants so vulnerable when their surfactant system is not yet ready.